This is one of the strangest biotech reactions of the week.
Moderna's personalised cancer vaccine, intismeran, combined with Merck's Keytruda showed in more than 1,100 melanoma patients:
42% lower risk of recurrence or death
38% lower risk of distant metastasis or death
No new safety signals
Those sound like excellent Phase 3 results.
Yet MRNA collapsed roughly 17.6%, briefly touching $183 before recovering toward $200.
So what went wrong?
I think the answer is simple:
The science beat the control arm. It did not beat the market's expectations.
๐ข WHAT THE TRIAL ACTUALLY PROVED
The biggest positive is not merely the 42% number.
Moderna has now taken personalised mRNA cancer therapy through a large Phase 3 study and demonstrated meaningful clinical benefit.
That matters because the entire post-Covid Moderna thesis depends on one question:
Can mRNA become a platform rather than a one-product success?
Melanoma moves Moderna closer to answering yes.
But there is an important distinction.
One successful cancer vaccine does not yet validate an entire oncology platform.
That is what the market is wrestling with.
๐ด WHY MRNA SOLD OFF
Expectations had become enormous.
MRNA ran toward $250+ before the data.
Investors were not merely pricing:
โThe melanoma trial succeeds.โ
They were beginning to price:
โModerna has cracked personalised cancer vaccines.โ
Those are completely different statements.
The results validated one indication.
The market wanted evidence that the technology could eventually work across many cancers.
That evidence still needs to come.
Hence the brutal:
Buy the expectation โ sell the confirmation.
๐ง THE NEXT DATA MATTERS MORE THAN THIS SELLOFF
This is where I think the opportunity becomes interesting.
If intismeran subsequently succeeds across additional tumour types, today's melanoma data stops looking like a single successful drug.
It starts looking like platform validation.
That could completely change how Moderna is valued.
The progression I am watching is:
Melanoma success
โ
Second cancer success
โ
Third indication
โ
Platform confidence
โ
Completely different valuation
The second major oncology success may therefore matter more to MRNA than improving the melanoma result from 42% to 45%.
AND MERCK TELLS US SOMETHING IMPORTANT
Merck barely moved compared with Moderna.
That makes sense.
Keytruda is already a massive established franchise.
For Merck, intismeran is another potential extension of an existing oncology empire.
For Moderna, it is potentially the proof that the company has a future beyond Covid vaccines.
Same trial.
Completely different stakes.
๐ฆ MY MRNA LEVELS
Current: ~$200
๐ก $195-$205: HOLD / WATCH
The stock is trying to stabilise after capitulation.
๐ข $180-$190: FIRST PICK
The $183 flush makes this the first area I would watch closely.
๐ข $165-$175: PREFERRED PICK
Much better asymmetry if the oncology thesis remains intact.
๐ด Below $160: THESIS CHECK
On recovery:
๐ก $215-$220: FIRST RECLAIM
๐ข $230-$235: BULLISH CONFIRMATION
๐ข $250+: DATA MOMENTUM RETURNS
๐ฎ MY NEXT 2-4 WEEK VIEW
๐ก 50% BASE: $185-$220
MRNA digests the enormous pre-data run and subsequent selloff.
๐ข 30% BULL: $220-$240
Investors reconsider the magnitude of the Phase 3 success and bargain hunters return.
๐ด 20% BEAR: $165-$185
The market continues unwinding the expectations premium.
MY CALL
I would not interpret the 17% collapse as evidence that Moderna's cancer vaccine failed.
It did not.
I would interpret it as evidence that MRNA's valuation had run ahead of what one successful trial could prove.
That distinction matters.
The next stage is no longer:
โDoes intismeran work in melanoma?โ
We now have a strong answer.
The bigger question is:
โCan Moderna reproduce this across cancer?โ
One successful Phase 3 trial creates a drug.
Repeated success across tumours could create a platform.
And the difference between those two outcomes could eventually be worth far more than this week's 17% move.
At $200, I watch.
At $180-$190, I become interested.
But the real buy signal I want is not another green candle.
It is another cancer indication working.
That is when expectations finally start catching up with the science for the right reason.
I am not a financial advisor. Trade wisely, Comrades!
MRNA at $200: overreaction to good data, or was the platform premium simply too high?
If you find this post interesting, give it wings! ๐ชฝ Repost and share the insights.
Do consider โFollow meโ and get firsthand read of my daily new post. Thank you.
@TigerPM @TigerStars @Daily_Discussion @TigerEvents @Tiger_SG
Comments